RA0357

antibody from Oursmab

Targeting: IL1B IL-1B, IL1-BETA, IL1F2

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0357

Provider

Oursmab

Product name

Gevokizumab (Biosimilar Reference Antibody) (IL1B)

Antibody type

Monoclonal

Description

Gevokizumab (development code XOMA-052) is an investigational, humanized monoclonal IgG2 antibody developed for the treatment of auto-inflammatory diseases. It represents a unique approach within the class of interleukin-1 beta (IL-1¦Â) inhibitors. Gevokizumab functions as an allosteric modulator of the IL-1¦Â pathway. Unlike direct neutralizing antibodies, it binds to a specific, allosteric site on the IL-1¦Â molecule itself. This binding reduces the affinity of IL-1¦Â for its type I receptor (IL-1RI) without completely blocking the interaction. By modulating rather than completely inhibiting the signal, gevokizumab aims to dampen the excessive inflammatory response driven by IL-1¦Â while potentially preserving some of its physiological functions, thereby offering a targeted and potentially safer anti-inflammatory effect.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.